2. Ninety-five per cent confidence intervals (CIs) were used and P-values ≤0.05 were considered to be statistically significant. All analyses were conducted using stata version SE 11.1 (StataCorp, College Station, TX). FK866 cost A total of 15 745 patients were registered at IDI between 2005 and 2009. By the end of 2009, 8833 patients were still in active follow-up. Median CD4 counts at registration increased from 66 cells/μL [interquartile range (IQR) 0, 234 cells/μL] in 2005 to 108 cells/μL (IQR 0, 426 cells/μL) in 2009.

With the exception of 2006, the annual proportion of patients who were eligible for ART (defined by a CD4 count <200 cells/μL and/or WHO stage IV) and initiated ART increased from 55.8% in 2005 to 69.2% in 2008, with a temporary decrease in 2006 (37.7%). The median time from registration to ART initiation decreased

over time [from 99 (IQR 43, 355) days in 2005 to 53 (IQR 28, 84) days in 2009], again with a temporary increase in 2006 [191 (IQR 69, 416) days]. Proportions of LFU in the first year of ART remained relatively stable at approximately 10%. A total of 7659 HIV-infected adults who started first-line ART between January 2005 and December 2009 were included in the study, of whom 4929 (64%) were women. The mean age was 37 years [standard check details deviation (SD) 9 years] and the median baseline CD4 count at ART initiation was 109 cells/μL (IQR 38, 176 cells/μL). Data

on baseline CD4 cell count were not available for 740 patients (10%). A regimen consisting of d4T+3TC+NVP was initiated in 3544 patients (46%), and 2971 (39%) started a regimen of ZDV+3TC+EFV. Characteristics of the patients included by year of ART initiation are shown in Table 1, and showed no difference over time except for initial ART Celecoxib regimen and baseline CD4 cell count. The median baseline CD4 count at ART initiation in 2005 was 82 cells/μL (IQR 24, 153 cells/μL) and increased every year to 148 cells/μL (IQR 61, 197 cells/μL) in 2008 and 139 cells/μL (IQR 62, 194 cells/μL) in 2009, except in 2006 [71 cells/μL (IQR 23, 154 cells/μL)]. The temporal trend in increasing baseline CD4 cell count was statistically significant (P < 0.001; Table 1 and Fig. 1). The 7659 patients contributed 6017 person-years of follow-up. Overall, 338 patients died in the first year after ART initiation. The overall mortality rate was 5.6/100 PYAR (95% CI 5.1–6.3 PYAR). The mortality rate fell from 6.5/100 PYAR (95% CI 5.5–7.6 PYAR) in 2005 to 3.6/100 PYAR (95% CI 2.2–5.8 PYAR) in 2009 (log-rank test for equality of survivor functions: P < 0.001) (Fig. 2). We performed Cox proportional hazards models of the association of various factors with mortality in the first year of ART (Table 2). Lower baseline CD4 cell count, male sex and older age were associated with an increased mortality risk.